Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

228

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

Glaucoma

Interventions

DRUG

BL1107 Low dose

Dosed twice daily for 28 days.

DRUG

BL1107 High dose

Dosed twice daily for 28 days.

DRUG

Timolol maleate 0.5%

Dosed twice daily for 28 days.

All Listed Sponsors

lead

Bausch & Lomb Incorporated

INDUSTRY